Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04996589
Other study ID # NL76207.091.20
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 8, 2021
Est. completion date July 27, 2021

Study information

Verified date August 2021
Source Wageningen University and Research
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

There are currently no minimally invasive techniques for the measurement of lipopolysaccharide (LPS) and Apo-B48 that can be used in samples collected in field settings. In this project we want to explore whether postprandial assessment of biomarkers LPS and ApoB48 in blood withdrawn with a finger prick test can be used as marker for low grade inflammation and risk factor for CVD. The primary objectives of this pilot study are to a) determine whether postprandial LPS and ApoB48 levels can be assessed in finger prick blood of both lean subjects and obese subjects; and b) compare postprandial LPS and ApoB48 levels assessed in venous blood and blood collected through a finger prick test. This study is an observational pilot study in which postprandial LPS and ApoB48 will be assessed before and after ingestion of a high fat load in 5 lean and 5 obese subjects in the age range 18-70 years. Samples will be collected under fasting conditions and in response to a high fat challenge test (1, 2, 4 and 6 hours post ingestion). The risks for participation are very small if not negligible. No adverse effects of the high fat challenge were reported previously. Consumption of high amounts of saturated fat may cause some GI discomfort. Blood sampling will be performed via a cannula and the insertion can be a painful and may cause a bruise. Finger prick might also give a short pain sensation and small bruises. The amount of blood that is drawn from participants is relatively small (total 37.5 ml) and is therefore within acceptable limits. There are no direct benefits for the participants. In the BIOLOGIC study we include both lean subjects and obese subjects as we expect differences in postprandial responses related to differences in chylomicron production and LPS levels. Therefore it is important to explore these biomarkers in both target groups. This study can therefore be regarded as group-related, non-therapeutic research.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date July 27, 2021
Est. primary completion date July 27, 2021
Accepts healthy volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Age 18-70 years - Living in the surroundings of Wageningen (max. 25 km) - Stable body weight for past 6 months - Suitable veins for insertion of cannula - BMI 18.5-22 kg/m2 (lean subjects) - BMI = 30 kg/m2 (obese subjects) Exclusion Criteria: - Use of cholesterol-lowering medication (e.g. statins) - Use of diabetes medication (e.g. insulin, metformin) - Use of antibiotics or anti-inflammatory medication (e.g. NSAIDS such as ibuprofen) - Known allergy for any of the food components used in the study (milk, cream, sugars) - Blood clotting disorders - Current smokers - Alcohol consumption of > 21 units per week - Participation in another clinical trial at the same time - Being an employee of Wageningen Food & Biobased Research

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Netherlands Stichting Wageningen Research Wageningen Gelderland

Sponsors (1)

Lead Sponsor Collaborator
Wageningen University and Research

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary LPS_B1 Serum levels LPS venous blood samples under fasting conditions Baseline
Primary ApoB48_B1 Serum levels ApoB48 venous blood samples under fasting conditions Baseline
Primary LPS_B2 Serum levels LPS finger prick blood under fasting conditions Baseline
Primary ApoB48_B2 Serum levels ApoB48finger prick blood under fasting conditions Baseline
Primary LPS1-1 Serum levels LPS venous blood samples after high-fat shake intake 1 hour post ingestion
Primary ApoB48_1-1 Serum levels ApoB48 venous blood samples after high-fat shake intake 1 hour post ingestion
Primary LPS1-2 Serum levels LPS finger prick blood after high-fat shake intake 1 hour post ingestion
Primary ApoB48_1-2 Serum levels ApoB48 finger prick blood after high-fat shake intake 1 hour post ingestion
Primary LPS2-1 Serum levels LPS venous blood samples after high-fat shake intake 2 hours post ingestion
Primary ApoB48_2-1 Serum levels ApoB48 venous blood samples after high-fat shake intake 2 hours post ingestion
Primary LPS2-2 Serum levels LPS finger prick blood after high-fat shake intake 2 hours post ingestion
Primary ApoB48_2-2 Serum levels ApoB48 finger prick blood after high-fat shake intake 2 hours post ingestion
Primary LPS4-1 Serum levels LPS venous blood samples after high-fat shake intake 4 hours post ingestion
Primary ApoB48_4-1 Serum levels ApoB48 venous blood samples after high-fat shake intake 4 hours post ingestion
Primary LPS4-2 Serum levels LPS finger prick blood after high-fat shake intake 4 hours post ingestion
Primary ApoB48_4-2 Serum levels ApoB48 finger prick blood after high-fat shake intake 4 hours post ingestion
Primary LPS6-1 Serum levels LPS venous blood samples after high-fat shake intake 6 hours post ingestion
Primary ApoB48_6-1 Serum levels ApoB48 venous blood samples after high-fat shake intake 6 hours post ingestion
Primary LPS6-2 Serum levels LPS finger prick blood after high-fat shake intake 6 hours post ingestion
Primary ApoB48_6-2 Serum levels ApoB48 finger prick blood after high-fat shake intake 6 hours post ingestion
Secondary LBP_B Plasma LBP levels in venous blood samples collected under fasting conditions Baseline
Secondary LBP_1 Plasma LBP levels in venous blood samples after high-fat shake intake 1 hour post ingestion
Secondary LBP_2 Plasma LBP levels in venous blood samples after high-fat shake intake 2 hours post ingestion
Secondary LBP_4 Plasma LBP levels in venous blood samples after high-fat shake intake 4 hours post ingestion
Secondary LBP_6 Plasma LBP levels in venous blood samples after high-fat shake intake 6 hours post ingestion
Secondary sCD14_B Plasma sCD14 levels in venous blood samples collected under fasting conditions Baseline
Secondary sCD14_1 Plasma sCD14 levels in venous blood samples after high-fat shake intake 1 hour post ingestion
Secondary sCD14_2 Plasma sCD14 levels in venous blood samples after high-fat shake intake 2 hours post ingestion
Secondary sCD14_4 Plasma sCD14 levels in venous blood samples after high-fat shake intake 4 hours post ingestion
Secondary sCD14_6 Plasma sCD14 levels in venous blood samples after high-fat shake intake 6 hours post ingestion
See also
  Status Clinical Trial Phase
Recruiting NCT03219593 - Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer Phase 2
Active, not recruiting NCT04681040 - Risk Stratification of COVID-19 Using Urine Biomarkers
Recruiting NCT05372172 - Tennessee Alzheimer's Project
Recruiting NCT06096766 - the Correlation Between Ovarian Function and Serum Biomarkers
Completed NCT04103632 - Screening and Diagnosing Exercise-induced Bronchoconstriction in Recreational Young Athletes (12-18 y) N/A
Completed NCT01159730 - Study to Assess the Safety and Efficacy of Multiple Doses of VB-201 on Biomarkers Phase 2
Completed NCT04507724 - The Use of Biochemical Analyzes to Monitor the Development of Wounds
Completed NCT06338111 - Can we Improve Mortality Prediction in Patients With Sepsis in the Emergency Department
Active, not recruiting NCT05027165 - Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab
Not yet recruiting NCT02931136 - Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging Phase 4
Not yet recruiting NCT03739892 - Biomarkers to Predict Gain From Therapy in Motor Stroke N/A
Recruiting NCT03801681 - ARrhythmias in MYocarditis
Recruiting NCT05372965 - The Effects of Smoking on miRNA-223 Before-After Non-Surgical Periodontal Therapy in Patients With Stage-3, Grade-B Periodontitis N/A
Completed NCT04772495 - miRNA Biomarkers in Multiple Sclerosis
Active, not recruiting NCT06178692 - Validation Study of a Serum-miRNA Signature in Glioma Patients.
Recruiting NCT04931537 - Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.
Recruiting NCT05090410 - Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate Phase 3
Not yet recruiting NCT05764356 - Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II
Recruiting NCT02201446 - The Role of Circulating Soluble CD74 in Acute Lung Injury N/A
Not yet recruiting NCT05752890 - A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma